[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PA8462501A1 - Formula de liberacion prolongada - Google Patents

Formula de liberacion prolongada

Info

Publication number
PA8462501A1
PA8462501A1 PA19988462501A PA8462501A PA8462501A1 PA 8462501 A1 PA8462501 A1 PA 8462501A1 PA 19988462501 A PA19988462501 A PA 19988462501A PA 8462501 A PA8462501 A PA 8462501A PA 8462501 A1 PA8462501 A1 PA 8462501A1
Authority
PA
Panama
Prior art keywords
prolonged release
chlorhydrate
venlafaxine
offers
release formula
Prior art date
Application number
PA19988462501A
Other languages
English (en)
Inventor
John Clifton Clark
John Ulrick Lamer
Deborah Marie Sherman
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25508423&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PA8462501(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by American Home Prod filed Critical American Home Prod
Publication of PA8462501A1 publication Critical patent/PA8462501A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE RELACIONA CON UNA FORMULA POSOLOGICA Y DOSIS UNITARIA DE LA MISMA, DE CLORHIDRATO DE VENLAFAXINA, UN AGENTE ANTIDEPRESIVO, DE LIBERACION PROLONGADA SOBRE 24 HORAS, QUE OFRECE UN CONTROL MEJOR DE LAS CONCENTRACIONES PLASMATICAS QUE EL DE LAS FORMULAS CONVENCIONALES EN TABLETAS QUE DEBEN ADMINISTRARSE DOS O MAS VECES AL DIA, Y QUE TAMBIEN SE ASOCIA CON UNA INCIDENCIA MENOR DE NAUSEAS Y VOMITOS QUE LAS TABLETAS CONVENCIONALES. EN SU ASPECTO PRIMARIO, ESTA INVENCION OFRECE UN NUCLEO MEJORADO DE LOS ESFEROIDES DE LIBERACION PROLONGADA, QUE COMPRENDE CLORHIDRATO DE VENLAFAXINA Y CELULOSA MICROCRISTALINA, ES DECIR, SIN EL AGREGADO DE HIDROXIPROPILMETILCELULOSA.
PA19988462501A 1997-11-05 1998-10-30 Formula de liberacion prolongada PA8462501A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US96432897A 1997-11-05 1997-11-05

Publications (1)

Publication Number Publication Date
PA8462501A1 true PA8462501A1 (es) 2000-05-24

Family

ID=25508423

Family Applications (1)

Application Number Title Priority Date Filing Date
PA19988462501A PA8462501A1 (es) 1997-11-05 1998-10-30 Formula de liberacion prolongada

Country Status (39)

Country Link
EP (1) EP1028718B1 (es)
JP (1) JP2001521892A (es)
KR (1) KR20010031797A (es)
CN (1) CN1278165A (es)
AR (1) AR014012A1 (es)
AT (1) ATE237320T1 (es)
AU (1) AU747978B2 (es)
BG (1) BG104397A (es)
BR (1) BR9813179A (es)
CA (1) CA2305242A1 (es)
CL (1) CL2004001705A1 (es)
CO (1) CO5011060A1 (es)
CZ (1) CZ20001659A3 (es)
DE (1) DE69813602T2 (es)
DK (1) DK1028718T3 (es)
EA (1) EA200000487A1 (es)
EE (1) EE04577B1 (es)
ES (1) ES2196620T3 (es)
GE (1) GEP20043198B (es)
HK (1) HK1029056A1 (es)
HR (1) HRP20000213B1 (es)
HU (1) HU225238B1 (es)
ID (1) ID26317A (es)
IL (1) IL135457A0 (es)
MA (1) MA24691A1 (es)
NO (1) NO20002126L (es)
NZ (1) NZ504460A (es)
PA (1) PA8462501A1 (es)
PE (1) PE128699A1 (es)
PL (1) PL341141A1 (es)
PT (1) PT1028718E (es)
SK (1) SK6472000A3 (es)
SV (1) SV1998000131A (es)
TR (1) TR200001232T2 (es)
TW (1) TW555568B (es)
UA (1) UA77145C2 (es)
UY (2) UY25234A1 (es)
WO (1) WO1999022724A2 (es)
ZA (1) ZA9810081B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2305606T3 (es) * 1999-04-06 2008-11-01 Sepracor Inc. Succinato de o-desmetilvenlafaxina.
SK286865B6 (sk) * 1999-05-20 2009-06-05 Elan Pharma International Limited Multičasticový farmaceutický prostriedok s riadeným uvoľňovaním selektívneho inhibítora spätného príjmu serotonínu a jeho použitie
IL146462A (en) 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
KR20050044673A (ko) * 2001-12-05 2005-05-12 와이어쓰 벤라팍신 하이드로클로라이드의 신규한 결정 다형체 및이의 제조방법
WO2003050074A1 (en) * 2001-12-13 2003-06-19 Cadila Healthcare Limited Manufacture of venlafaxine hydrochloride and crystalline polymorphs thereof
EP1474123A1 (en) * 2002-01-03 2004-11-10 LEK Pharmaceuticals D.D. Controlled release pharmaceutical formulation containing venlafaxine
WO2003082806A1 (en) * 2002-03-28 2003-10-09 Synthon B.V. Venlafaxine base
AR039164A1 (es) 2002-03-28 2005-02-09 Synthon Bv Sales de venlafaxina de baja solubilidad en agua
WO2003082804A1 (en) 2002-03-28 2003-10-09 Synthon B.V. Venlafaxine besylate
AU2003219117A1 (en) * 2002-03-28 2003-10-13 Synthon B.V. Extended release venlafaxine formulations
FR2845289B1 (fr) 2002-10-04 2004-12-03 Ethypharm Sa Spheroides, procede de preparation et compositions pharmaceutiques.
CA2415154C (en) * 2002-12-24 2009-06-16 Biovail Laboratories Inc. Modified release formulations of selective serotonin re-uptake inhibitors
DE10350194B4 (de) * 2003-10-28 2005-11-10 Bioplanta Arzneimittel Gmbh Verwendung von Extrakten aus Opuntien zur Behandlung von depressiven Verstimmungen und Erkrankungen
TW200503670A (en) * 2003-03-28 2005-02-01 Sandoz Ag Venlafaxine compositions
SI1502587T1 (sl) * 2003-07-30 2007-02-28 Pharmathen Sa Formulacija z zadrzevanim sproscanjem za Venlafaxin hidroklorid
HUP0303382A2 (hu) * 2003-10-10 2005-08-29 EGIS Gyógyszergyár Rt. Venlafaxin-hidroklorid-tartalmú pelletek
KR20070000439A (ko) 2004-02-04 2007-01-02 알렘빅 리미티드 벤라팍신 히드로클로라이드의 방출연장형 코팅 미니정제
US7776358B2 (en) 2004-07-22 2010-08-17 Synthon Ip Inc. Extended release venlafaxine besylate tablets
CA2648278C (en) * 2006-04-03 2019-05-28 Isa Odidi Drug delivery composition
WO2007129329A2 (en) * 2006-05-08 2007-11-15 Jubilant Organosys Limited Extended release pharmaceutical formulation comprising venlafaxine hydrochloride
CN102772390B (zh) * 2012-08-16 2014-01-08 乐普药业股份有限公司 一种盐酸文拉法辛缓释胶囊及其制备方法
FR3080278B1 (fr) * 2018-04-11 2021-04-30 Ghs Patents Ltd Procede de fabrication d'un spheroide de cannabidiol

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1561204A (en) * 1977-06-01 1980-02-13 Ici Ltd Sustained release pharmaceutical composition
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
ZA97976B (en) * 1996-04-05 1997-08-18 Alza Corp Uniform drug delivery theraphy.

Also Published As

Publication number Publication date
DK1028718T3 (da) 2003-07-28
TW555568B (en) 2003-10-01
JP2001521892A (ja) 2001-11-13
HK1029056A1 (en) 2001-03-23
PT1028718E (pt) 2003-07-31
HUP0004287A2 (hu) 2002-04-29
EE200000212A (et) 2001-04-16
GEP20043198B (en) 2004-03-25
SK6472000A3 (en) 2000-11-07
HUP0004287A3 (en) 2002-05-28
BG104397A (en) 2001-02-28
CA2305242A1 (en) 1999-05-14
UY25234A1 (es) 2000-12-29
AR014012A1 (es) 2001-01-31
MA24691A1 (fr) 1999-07-01
ZA9810081B (en) 2000-05-04
DE69813602D1 (de) 2003-05-22
IL135457A0 (en) 2001-05-20
NO20002126D0 (no) 2000-04-26
SV1998000131A (es) 1999-11-18
TR200001232T2 (tr) 2000-12-21
KR20010031797A (ko) 2001-04-16
BR9813179A (pt) 2000-08-22
ID26317A (id) 2000-12-14
ATE237320T1 (de) 2003-05-15
AU1300399A (en) 1999-05-24
PL341141A1 (en) 2001-03-26
HRP20000213B1 (en) 2004-04-30
WO1999022724A2 (en) 1999-05-14
EE04577B1 (et) 2006-02-15
CO5011060A1 (es) 2001-02-28
EP1028718B1 (en) 2003-04-16
EP1028718A2 (en) 2000-08-23
ES2196620T3 (es) 2003-12-16
UY25692A1 (es) 2000-03-31
NZ504460A (en) 2003-01-31
HRP20000213A2 (en) 2000-12-31
WO1999022724A3 (en) 1999-07-22
PE128699A1 (es) 2000-01-06
HU225238B1 (en) 2006-08-28
CL2004001705A1 (es) 2005-06-03
AU747978B2 (en) 2002-05-30
NO20002126L (no) 2000-05-04
CZ20001659A3 (cs) 2001-10-17
DE69813602T2 (de) 2003-11-06
EA200000487A1 (ru) 2000-10-30
UA77145C2 (en) 2006-11-15
CN1278165A (zh) 2000-12-27

Similar Documents

Publication Publication Date Title
PA8462501A1 (es) Formula de liberacion prolongada
PA8426401A1 (es) Formula de liberacion prolongada
PA8481601A1 (es) Desnaturalizantes para las sales aminas simpaticomimeticas
PA8577901A1 (es) Formulacion farmaceutica
CR9609A (es) Formulaciones de una sal de bupropion de liberacion modificada
HN2002000300A (es) Nuevos derivados de piperazina
UY27740A1 (es) Nuevos compuestos
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
UY31403A1 (es) "derivados novedosos de ({((3-metilfenil)-2h-tetrazol-5-il)-etoxi} -4h-1,2,4-triazol-3-il), composiciones farmacéuticas conteniendolos y uso médico de los mismos".
ES2176106B1 (es) Comprimido matricial de liberacion prolongada de trimetazidina tras su administracion por via oral.
BRPI0017528B8 (pt) uso de uma composição contendo sal de cetotifeno
AR025046A1 (es) Inhibidores il-5 no esteroidales, procedimientos e intermediarios para su preparacion y composiciones farmaceuticas que comprenden dichos inhibidores
HN2001000235A (es) Derivados puentes de piperazina
TR200003156T2 (tr) Bir aktif içerik olarak izomalt içeren terapötik soğuk algınlığına karşı ajan.
AR041678A1 (es) Formas cristalinas de clorhidrato de donepezil
ES2305567T3 (es) Formulaciones de tramadol de liberacion sostenida con una eficacia de 24 horas.
BR0210327A (pt) Microcápsulas para proteção do hálito
AR016473A1 (es) Preparado efervescente y procedimiento para su preparacion
HN2001000021A (es) Nuevos derivados de amidas heterociclicas
AR003093A1 (es) Nuevos derivados de imidazol-n-bencildioxol, su procedimiento de preparacion, su aplicacion a titulo de medicamentos, composicionesfarmaceuticas y nueva utilizacion.
ECSP982704A (es) Formula de liberacion prolongada
HN2001000119A (es) S-metil-dihidro -ziprasidona para el tratamiento de trastornos psiquiatricos y oculares.
GT200100218A (es) Compuesto agroquimico.
ECSP972046A (es) Formula de liberacion prolongada
BRPI0410710A (pt) composições e métodos que compreendem compostos de gastrina e seus usos